Skip to content
Peptide research

Semaglutide

Also known as Ozempic · Wegovy · Rybelsus
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
FDA-approved

A modified GLP-1 receptor agonist marketed for weight loss and type 2 diabetes. Human evidence is strong, with large trials backing weight loss, glycemic control, and cardiovascular benefits, though neuroprotective claims stay speculative. Main risk is GI side effects in many users, plus a boxed thyroid-tumor warning (animal studies) and contraindication in MEN 2 or medullary thyroid cancer history. FDA-approved; obtain only through a licensed prescriber.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Semaglutide is a lab-made version of GLP-1, a natural hormone your body releases after eating to signal fullness. It's nearly identical to the natural hormone (94% match) but engineered to last much longer in the body: about seven days per dose instead of minutes. Sold under the brand names Ozempic, Wegovy, and Rybelsus, it is FDA-approved for type 2 diabetes, weight management, and reducing the risk of heart attack and stroke.

How it works in the body

A GLP-1 receptor agonist with 94% similarity to natural GLP-1. A key modification (aminobutyric acid at position 8 + C18 fatty diacid) provides albumin binding for a 7-day half-life. It activates GLP-1 receptors in the pancreas (insulin), brain (appetite suppression), and heart (cardioprotection).

Research overview

Semaglutide works by mimicking your body's natural fullness signal. It prompts the pancreas to release insulin when blood sugar is high, suppresses the hormone that raises blood sugar (glucagon), slows the rate food leaves your stomach (so you feel full longer), and acts on appetite centers in the brain to reduce hunger. A fatty acid chain attached to the molecule lets it bind to a blood protein called albumin, extending its activity to about one week per dose. It also has anti-inflammatory effects. Semaglutide has one of the strongest clinical evidence bases of any peptide, with over 40,000 participants across dozens of large-scale trials.

Who researches Semaglutide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those with Personal/family history of medullary thyroid carcinoma (MTC)

    Absolute

    GLP-1 agonists caused thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.

  • Those with History of pancreatitis

    High

    GLP-1 agonists may increase pancreatitis risk. Use with extreme caution if prior pancreatitis.

  • Those with Severe gastroparesis

    High

    Semaglutide slows gastric emptying. Can worsen severe gastroparesis significantly.

  • Those who are pregnant or breastfeeding

    Absolute

    Discontinue at least 2 months before planned conception. Animal studies show fetal harm.

  • Those with Type 1 diabetes

    Absolute

    Not indicated for T1DM. Risk of diabetic ketoacidosis.

  • Those with Severe renal impairment

    Moderate

    GI side effects (nausea, vomiting) may worsen dehydration and renal function.

Safety & interactions

Do not use if

  • Personal/family history of medullary thyroid carcinoma (MTC)

    Absolute

    GLP-1 agonists caused thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.

  • Type 1 diabetes

    Absolute

    Not indicated for T1DM. Risk of diabetic ketoacidosis.

  • History of pancreatitis

    High

    GLP-1 agonists may increase pancreatitis risk. Use with extreme caution if prior pancreatitis.

  • Severe gastroparesis

    High

    Semaglutide slows gastric emptying. Can worsen severe gastroparesis significantly.

  • Severe renal impairment

    Moderate

    GI side effects (nausea, vomiting) may worsen dehydration and renal function.

General cautions

  • Pregnancy or planning pregnancy

    Absolute

    Discontinue at least 2 months before planned conception. Animal studies show fetal harm.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(7)

Rated by level of concern

  • GI side effects: nausea (20-44%), vomiting, diarrhea, constipation

    High

    PMID 33567185 (STEP 1); FDA Wegovy/Ozempic prescribing information, Adverse Reactions

  • Boxed warning: thyroid C-cell tumors in animal studies (human relevance unclear)

    Moderate

    FDA Ozempic/Wegovy prescribing information, Boxed Warning; SUSTAIN/STEP program safety data

  • Pancreatitis risk (rare)

    Low

    FDA Ozempic prescribing information, Warnings and Precautions (Pancreatitis); PMID 37952131 (SELECT safety)

  • Gallbladder disease risk

    Moderate

    PMID 33567185 (STEP 1); He et al., JAMA Intern Med 2022, GLP-1 RA gallbladder/biliary meta-analysis

  • Acute kidney injury (rare, usually from dehydration due to GI effects)

    Low

    FDA Ozempic prescribing information, Warnings and Precautions (Acute Kidney Injury); Perkovic et al., NEJM 2024 (FLOW)

  • Diabetic retinopathy complications

    Moderate

    PMID 27633186 (SUSTAIN-6); FOCUS trial (NCT03811561); FDA Ozempic prescribing information, Warnings and Precautions (Diabetic Retinopathy Complications)

  • Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2

    High

    FDA Ozempic/Wegovy prescribing information, Contraindications

Interaction summary(9)

Rated by direction with this peptide

  • Insulin (basal or prandial)

    CautionHigh

    Additive glucose lowering causes clinically significant hypoglycemia; the label directs reducing the insulin dose when semaglutide is added, and this is one of the few genuinely dangerous, well-documented interactions.

    FDA Ozempic prescribing information, Warnings and Precautions (Hypoglycemia) and Dosage and Administration

  • Sulfonylureas (glipizide, glyburide, glimepiride)

    CautionHigh

    Insulin-secretagogue plus incretin agonist markedly raises severe hypoglycemia risk; sulfonylurea dose reduction or discontinuation is standard practice at semaglutide initiation.

    FDA Ozempic prescribing information, Warnings and Precautions (Hypoglycemia); PMID 27633186 (SUSTAIN-6 hypoglycemia data)

  • General anesthesia and procedural sedation

    CautionModerate

    Delayed gastric emptying can leave residual gastric contents despite standard fasting, and the ASA issued 2023 consensus guidance on holding GLP-1 agonists before elective procedures because of pulmonary aspiration risk; endoscopy series have documented retained food.

    American Society of Anesthesiologists, Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists (June 2023)

  • Warfarin and other narrow-therapeutic-index oral drugs

    CautionLow

    Semaglutide slows gastric emptying and can alter the rate of oral absorption. Dedicated PK studies with warfarin showed no clinically relevant change in overall exposure or INR, so this is a monitoring-level precaution during initiation and titration rather than a demonstrated clinical interaction.

    FDA Ozempic prescribing information, Drug Interactions and Clinical Pharmacology (drug interaction studies)

  • Levothyroxine (particularly with oral semaglutide/Rybelsus)

    CautionModerate

    The SNAC absorption enhancer in oral semaglutide increases total levothyroxine exposure by roughly 33%, so thyroid function should be monitored; the two must also be dosed apart given Rybelsus's strict fasting-plus-30-minute administration requirement.

    FDA Rybelsus prescribing information, Drug Interactions

  • Diuretics, ACE inhibitors/ARBs, and NSAIDs during GI illness

    CautionModerate

    Volume depletion from semaglutide-induced vomiting or diarrhea, added to these agents, is the usual pathway to acute kidney injury; sick-day rules apply rather than avoidance. Mechanistic and postmarketing rather than trial-demonstrated.

    FDA Ozempic prescribing information, Warnings and Precautions (Acute Kidney Injury)

  • Other GLP-1 receptor agonists and DPP-4 inhibitors

    CautionLow

    Pharmacologically redundant - combining offers no incremental efficacy while compounding GI adverse effects, and co-prescription with another GLP-1 RA is not recommended. This is therapeutic duplication rather than a toxicity interaction.

    ADA Standards of Care, Pharmacologic Approaches to Glycemic Treatment

  • SGLT2 inhibitors (empagliflozin, dapagliflozin)

    SynergisticLow

    Complementary mechanisms with additive glycemic and weight benefit and no hypoglycemia liability; randomized data (SUSTAIN 9: semaglutide added to background SGLT2 inhibitor) support the combination, and both classes independently carry cardiovascular and renal outcome evidence.

    Zinman et al., Lancet Diabetes Endocrinol 2019 (SUSTAIN 9); ADA Standards of Care

  • Combined oral contraceptives

    NeutralLow

    Dedicated PK studies found no clinically relevant reduction in ethinyl estradiol or levonorgestrel exposure with semaglutide, so no backup contraception is required on pharmacokinetic grounds - though pregnancy must be avoided and the drug stopped 2 months before a planned pregnancy.

    FDA Ozempic prescribing information, Drug Interactions and Use in Specific Populations (Pregnancy)

Known risks(7)

  • GI side effects: nausea (20-44%), vomiting, diarrhea, constipation

  • Boxed warning: thyroid C-cell tumors in animal studies (human relevance unclear)

  • Pancreatitis risk (rare)

  • Gallbladder disease risk

  • Acute kidney injury (rare, usually from dehydration due to GI effects)

  • Diabetic retinopathy complications

  • Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2

Drug interactions(3)

  • Tirzepatide

    Both are GLP-1 agonists. Combining would increase GI side effects and hypoglycemia risk.

  • Insulin

    Increased hypoglycemia risk. Dose reduction of insulin may be needed.

  • Oral medications

    Slowed gastric emptying may affect absorption of oral drugs. Take oral meds 1+ hour before semaglutide.

Research & benefits

Evidence base

Evidence Level
Level 1 — Strong
Total Studies
288
Human Participants
40000

Over 40,000 participants across dozens of Phase 3 RCTs. Evidence supports weight loss, T2DM, CV risk reduction, CKD.

Researched for(7)

Rated by confidence in the evidence

  • Significant weight loss

    High

    Large randomized trial showed 14.9% body weight loss versus 2.4% with placebo.

    PMID 33567185 (Wilding et al., NEJM 2021, STEP 1); FDA Wegovy prescribing information

  • Type 2 diabetes control

    High

    Multiple large trials showed HbA1c reductions of 1 to 1.8 percentage points versus placebo.

    FDA Ozempic and Rybelsus prescribing information (Clinical Studies); SUSTAIN and PIONEER phase 3 program (e.g. Ahren et al., Lancet Diabetes Endocrinol 2017, SUSTAIN 2)

  • Cardiovascular risk reduction

    High

    Two large outcome trials showed roughly 20 to 26% fewer major cardiovascular events.

    PMID 27633186 (Marso et al., NEJM 2016, SUSTAIN-6); PMID 37952131 (Lincoff et al., NEJM 2023, SELECT)

  • Kidney disease protection

    High

    Large kidney-outcomes trial stopped early after showing a 24% reduction in kidney disease progression.

    Perkovic et al., NEJM 2024 (FLOW); NCT03819153

  • Heart failure improvement

    High

    Trials show improved heart failure symptoms and function in obesity-related HFpEF, not mortality.

    Kosiborod et al., NEJM 2023 (STEP-HFpEF, NCT04788511); Kosiborod et al., NEJM 2024 (STEP-HFpEF DM, NCT04916470)

  • Neuroprotective potential

    Speculative

    Preliminary evidence only; phase 3 Alzheimer's trials failed to show significant benefit.

    NCT04777396 (EVOKE), NCT04777409 (EVOKE+), Novo Nordisk topline announcement 2025

  • Anti-inflammatory effects

    Medium

    Large trials show reduced inflammatory markers, but no clinical inflammatory-disease outcome tested.

    PMID 37952131 (SELECT, hsCRP secondary endpoint); PMID 33567185 (STEP 1, CRP secondary endpoint)

Benefits(7)

  • Significant weight loss

  • Type 2 diabetes control

  • Cardiovascular risk reduction

  • Kidney disease protection

  • Heart failure improvement

  • Neuroprotective potential

  • Anti-inflammatory effects

Key studies(5)

  1. Wilding JPH et al.

    NEJM

    2021

    14.9% mean weight loss vs 2.4% placebo over 68 weeks

  2. Lincoff AM et al.

    NEJM

    2023

    20% MACE reduction in 17,604 patients

  3. Marso SP et al.

    NEJM

    2016

    26% CV event reduction in 3,297 patients

  4. Perkovic V et al.

    NEJM

    2024

    24% reduction in major kidney events

  5. Wharton S et al.

    Lancet Diabetes Endocrinol

    2025

    21% mean weight loss, 90%+ achieved >=5%

What research suggests over time

  • Weeks 2-4

    STEP-1 (NEJM 2021)

    Reduced food cravings and ~2% weight loss during the initial low-dose titration phase.

  • Months 2-3

    STEP-1 / SUSTAIN

    ~6-9% weight loss as the dose climbs toward the target; meaningful A1c improvements in patients with diabetes.

  • Long-term

    Phase 3 RCT

    Mean 14.9% weight loss at 68 weeks in STEP 1. SELECT trial showed 20% MACE risk reduction over ~3 years.

Prescribing labels

FDA-Approved Labels

This page does not list doses. Each product below has an FDA label with its prescribing information.

Protocol
Ozempic (semaglutide) injection
Notes
Dosing is set by your prescriber and the FDA label.
Protocol
Wegovy (semaglutide) injection and tablets
Notes
Dosing is set by your prescriber and the FDA label.
Protocol
Rybelsus and Ozempic (semaglutide) tablets
Notes
Dosing is set by your prescriber and the FDA label.

Monitoring & labs

Baseline before starting, then per marker schedule during protocol.

Baseline labs(7)

  • Complete Blood Count (CBC)

    Optimal All markers within mid-range

    Establishes baseline for detecting hematological changes.

    Lab normal Standard reference ranges

  • Comprehensive Metabolic Panel (CMP)

    Optimal Liver enzymes <25, glucose 75–90, eGFR >90

    Liver and kidney function baseline.

    Lab normal Standard reference ranges

  • Fasting glucose + HbA1c

    Optimal 75–90 mg/dL

    Baseline metabolic markers — critical for tracking glucose regulation changes.

    Lab normal 65–99 mg/dL

  • Lipid panel

    Optimal ApoB <80, TG <80, HDL >55

    Cholesterol and triglyceride baseline for tracking cardiovascular metabolic effects.

    Lab normal TC <200, LDL <100, HDL >40, TG <150

  • Thyroid panel (TSH, free T3/T4)

    Optimal TSH 1.0–2.0; Free T3 upper third of range

    Thyroid function can be affected by metabolic peptides.

    Lab normal TSH 0.4–4.5

  • Amylase + Lipase

    Optimal Both within mid-range

    Baseline pancreatic markers — this peptide carries a documented pancreatitis risk.

    Lab normal Standard ranges

  • Calcitonin

    Optimal Under 5 pg/mL

    Baseline thyroid C-cell marker — this peptide carries a thyroid tumor risk warning.

    Lab normal Under 10 pg/mL (men)

Ongoing tracking(5)

  • Fasting glucose + HbA1c

    Every 4-8 weeksOptimal 75–90 mg/dL

    Track glucose regulation changes during protocol.

    Lab normal 65–99 mg/dL

  • Lipid panel

    Every 8-12 weeksOptimal ApoB <80, TG <80, HDL >55

    Monitor cholesterol and triglyceride response.

    Lab normal TC <200, LDL <100, HDL >40, TG <150

  • Liver enzymes (ALT/AST)

    Every 8 weeksOptimal ALT & AST under 25 U/L

    Hepatic function monitoring during metabolic modulation.

    Lab normal ALT 7–56, AST 10–40 U/L

  • Amylase + Lipase

    Every 8-12 weeksOptimal Both within mid-range

    Pancreatic enzyme monitoring — pancreatitis risk.

    Lab normal Standard ranges

  • Calcitonin

    Every 12 weeksOptimal Under 5 pg/mL

    Thyroid C-cell monitoring — MTC risk.

    Lab normal Under 10 pg/mL (men)

Retest schedule(6)

  1. Baseline

    critical

    Before starting

    Full baseline + thyroid panel, lipase, amylase, HbA1c, lipid panel.

  2. Early follow-up

    critical

    Week 4

    Recheck lipase, amylase, glucose. Most early-protocol concerns surface here.

  3. Second check

    critical

    Week 8

    Recheck metabolic markers and GI tolerance.

  4. Mid-protocol

    critical

    Week 12

    Comprehensive retest. Track HbA1c, weight, lipids, thyroid.

  5. Ongoing

    standard

    Every 12 weeks

    Sustained metabolic monitoring during chronic use.

  6. Post-protocol

    standard

    4-6 weeks after stopping

    Track for weight regain and metabolic rebound.

When to stop and reassess(7)

  • ALT or AST

    stop

    Above 2× upper limit of normal (>~80 U/L)

    Stop protocol and consult a provider — possible drug-induced liver injury.

  • eGFR

    stop

    Drop of >15 mL/min/1.73m² from baseline, or below 60

    Stop protocol and consult a provider — possible kidney function decline.

  • Symptoms

    stop

    New severe symptoms correlating with lab changes

    Stop protocol and seek medical evaluation immediately.

  • Lipase or amylase

    stop

    Above 3× upper limit of normal

    Stop protocol and seek urgent medical evaluation — possible pancreatitis.

  • Calcitonin

    consult

    Above 10 pg/mL or rising trend

    Consult an endocrinologist — possible thyroid C-cell stimulation.

  • Heart rate

    consult

    Sustained >100 bpm or new palpitations

    Consult a provider — GLP-1 agonists can affect cardiac rhythm.

  • Lipase

    stop

    Above 3× upper limit of normal

    Stop protocol and seek urgent medical evaluation — pancreatitis risk documented.

Lab monitoring helps track your body's response to Semaglutide. Any unexplained changes should prompt discussion with your prescribing provider.

Regulation & availability

Why researchers look at it

One of the most extensively studied weight-loss medicines, with 40,000+ trial participants showing 15-20% sustained weight loss and a 20% reduction in heart attacks and strokes. Research continues in addiction and liver disease; phase 3 Alzheimer's trials did not show clinical benefit. An oral formulation approved in late 2025 could widen access.

Estimated cost
Self-pay $349/mo for Wegovy or Ozempic pens ($399/mo for Wegovy HD, the highest Wegovy dose; $499/mo for Ozempic at its highest dose), pills from $149/mo (NovoCare, checked 21 Oct 2026); $60-299/mo compounded through telehealth; some providers add a membership fee
FDA status
Fully FDA-approved. Ozempic (Dec 2017), Rybelsus (Sept 2019), Wegovy (June 2021), Oral Wegovy (Dec 2025), a higher-dose Wegovy (early 2026). WHO Essential Medicine.
WADA status
Not prohibited under the 2026 WADA rules. Semaglutide markers are monitored in and out of competition. A TUE is not required for semaglutide itself.
Prescribability
FDA-approved prescription drug: Ozempic, Wegovy and Rybelsus. Compounding remains subject to federal restrictions; shortage-related exceptions ended in 2025.
Availability
Available by prescription as injectable and oral products. Compounding restrictions predate February 2026; 503A patient-specific exceptions require applicable conditions, including a documented significant difference when relevant.

International status

  • EU

    EMA-approved (Ozempic, Wegovy, Rybelsus)

  • UK

    MHRA-approved

  • US

    FDA-approved (Ozempic, Wegovy, Rybelsus)

  • Japan

    PMDA-approved (Ozempic)

  • Canada

    Health Canada-approved

  • Australia

    TGA-approved

Regulatory timeline(5)

  1. 2017-12
    Ozempic FDA approvalInjectable for T2DM
  2. 2019-09
    Rybelsus FDA approvalFirst oral GLP-1 for T2DM
  3. 2021-06
    Wegovy FDA approvalInjectable for weight management
  4. 2025-12
    Oral Wegovy approvalFirst oral GLP-1 for weight management
  5. 2025-02-21
    Shortage resolvedFDA ended shortage, tightened compounding rules

Sources & FAQs

Research sources(5)

Frequently asked questions(5)

Common side effects?

GI: nausea (20-44%), vomiting, diarrhea, constipation. Usually mild, diminish over time. Rare: pancreatitis, gallbladder disease.

Who should NOT take it?

Personal or family history of medullary thyroid carcinoma, MEN 2, or serious allergy to semaglutide or its ingredients. Type 1 diabetes is not a labeled contraindication. Suicidal thoughts require prompt clinical care but are not a labeled semaglutide contraindication.

Is compounded semaglutide available in 2026?

Restricted. The shortage ended February 2025. Qualifying 503A patient-specific compounding may remain possible; documented medical need alone does not permit 503B compounding from bulk semaglutide.

How much weight loss?

Wegovy injection: ~15-17% over 68 weeks. The higher Wegovy HD dose: ~21% over 72 weeks. Oral semaglutide at the obesity dose: ~16.6%. Individual results vary. Dosing is set by your prescriber and the FDA label.

Benefits beyond weight loss?

20-26% CV event reduction, 24% kidney event reduction, anti-inflammatory effects. EVOKE and EVOKE+ did not slow Alzheimer's progression; liver-disease research continues.